It is essential to modernize TB treatment options and, even with recent progress, we must strive for better, shorter, and simpler treatment options for patients with all forms of TB. As a pharmaceutical leader in the space, Johnson & Johnson advances R&D for TB by accelerating science in our own labs, convening prominent partners and contributing critical resources to research collaborations at every stage of clinical research.

UNITE4TB (academia and industry united innovation and treatment for tuberculosis) is a public-private collaboration with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. Over the next 7 years, the consortium will be active in approximately 40 trial sites on four continents (Europe, Asia, Africa and South America), with the goal of delivering novel phase 2 clinical trials that will accelerate the development of new TB drugs and regimens. Achieving this goal will facilitate fulfilment of one of the main unmet needs in the TB field: better-tolerated drug regimens of shorter duration that can be deployed to tackle tuberculosis across various drug-resistance patterns and co-morbidities. UNITE4TB is a project of the IMI AMR Accelerator, a public-private collaboration that aims to progress the development of new medicines to treat or prevent resistant bacterial infections.